---
document_datetime: 2025-04-30 10:55:17
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/filspari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: filspari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.479852
conversion_datetime: 2025-12-24 22:59:58.250181
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## FILSPARI

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                     |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------|
| II/0002              | Update of sections 4.8 and 5.1 of the SmPC based on final results from study 021IGAN17001 (PROTECT) listed as a specific obligation in Annex II; this is a randomized, multicenter, double-blind parallel-group, active control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathy. The Package Leaflet is updated | 27/02/2025                          | 23/04/2025                                  | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Filspari-H-C-II-002' |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | accordingly. As a result of this variation, the SmPC, Annex II and PL are also updated to reflect the completion of the specific obligation and the CHMP recommendation to grant a marketing authorisation no longer subject to specific obligation. The RMP version 1.0 is agreed. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.4 and to introduce editorial changes. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/11060 /202408 | Periodic Safety Update EU Single assessment - sparsentan                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 13/03/2025 | n/a        |                        | PRAC Recommendation - maintenance |
| R/0004              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 12/12/2024 | 12/02/2025 |                        |                                   |
| IB/0003             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                  | 03/09/2024 | n/a        |                        |                                   |
| IB/0001             | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                     | 26/06/2024 | 12/02/2025 | SmPC, Labelling and PL |                                   |